$287 Million

Natera

Follow-on Offering

Bookrunner, September 2020

Natera, Inc. is a diagnostic company with proprietary molecular and bioinformatics technology. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. The Company offers proprietary, genetic, non-invasive tests to evaluate risk, thus enabling early-detection of prenatal and oncology conditions. The use of blood-based diagnostic tests requires the measurement of very small amounts of relevant genetic material circulating within a much larger blood sample. Natera’s approach combines proprietary molecular biology and computational techniques to measure genomic variations in tiny amounts of DNA, as small as a single cell. Natera has a comprehensive suite of reproductive health products.

More Like This

Sep 2020
$86 Million

Follow-on Offering

Bookrunner

View Details
Sep 2020
$80 Million

Follow-on Offering

Lead Left Bookrunner

View Details
Sep 2020
$150 Million

Follow-on Offering

Lead Left Bookrunner

View Details